UKUK

Cancer individuality

06.02.2011

Cambridge – Patients with solid tumours bearing different cancer cell types might have a worse prognosis than those with homogeneous tumours, British researchers suggest (Brit. J. Cancer, 19th January). In tissue samples taken from patients with advanced cervical cancer, the team headed by James Brenton at Cambridge University found that tumour heterogeneity led to worse outcomes. CHG analyses up to 5 years post-treatment showed that patients without pre-existing tumour cell heterogeneity lived longer, and that heterogeneity seems to increase the probability for selection of tumour cells that were therapy-resistant right before initiation of radio­chemotherapy. Out of ten patients, two showed initial tumour cell heterogeneity and survival of one therapy-resistant tumour cell type after treatment. The results still need to be confimed by larger studies.

UKUK

22.12.2011

London - Nothing is well if the end is not well. For Astra Zeneca the end of 2011 isn't well at all. A new anti-ovarian cancer drug and a planned antidepressant have underperformed in tests. As a result, AstraZeneca will take a...

UKUK

17.12.2011

Surrey – The UK government is investing an additional £80m (€93.5m) to fund continued development of the Institute for Animal Health (IAH) at Pirbright, an institute of the Biotechnology and Biological Sciences Research Council...

UKUK

15.12.2011

Rijeka/London – Allergies like asthma or psoriasis might arise from environmental toxins, suggest researchers from Rijeka University (Croatia) and King’s College (London). In mice, they identified a special population of T cells...

UKUK

13.12.2011

London – Interesting times ahead in the European cancer treatment market. A report states that in the UK alone, diagnosis and treatment costs are likely to increase by 62%, from £9.4 billion in 2010 to £15.3 billion by 2021. The...

UKUK

12.12.2011

York - Tissue Regenix Group plc plans to raise €29m through the sale of 181.8 million shares. The regenerative medical device company is held within the IP Group portfolio and a spin-out company from the University of Leeds. The...

UKUK

11.12.2011

London – Cancer Research UK has begun recruiting patients in the first phase of its Stratified Medicine Programme, which is aimed at finding cancer biomarkers and establishing a genetic testing service in the UK. The charity’s...

UKUK

06.12.2011

London – British Prime Minister David Cameron is trying to come to the rescue of Britain’s embattled biopharmaceutical industry. He has earmarked €210m to support a “biomedical catalyst fund” to back early-stage academic and...

UKUK

06.12.2011

London - David Cameron plans to come to the rescue of Britain's embattled biopharmaceutical industry. The conservative prime minister has earmarked £180m (€210 million) to support a "biomedical catalyst fund" to back ...

UKUK

25.11.2011

Cancer Research UK has started recruiting patients in the first phase of its Stratified Medicine Program, which is seeking to find cancer biomarkers and establish a genetic testing service in the U.K. The charity's multi-million...

Displaying results 11 to 20 out of 396

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/browse/1/article/cancer-individuality.html

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR331.6%
  • SANTHERA (CH)69.50 CHF133.2%
  • ADDEX (CH)4.21 CHF95.8%

FLOP

  • MERCK KGAA (D)63.45 EUR-50.2%
  • THROMBOGENICS (B)8.55 EUR-40.5%
  • HYBRIGENICS (F)1.71 EUR-34.5%

TOP

  • SANTHERA (CH)69.50 CHF3375.0%
  • GW PHARMACEUTICALS (UK)415.25 GBP765.1%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • CYTOS (CH)0.27 CHF-92.1%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events